{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:16:18Z","timestamp":1786986978123,"version":"build-2736575974"},"reference-count":105,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cmi.2025.11.023","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:55:02Z","timestamp":1764291302000},"page":"740-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Invasive mould infection in children \u2013 advances made or obstacles remaining?"],"prefix":"10.1016","volume":"32","author":[{"given":"Daniel K.","family":"Yeoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen","family":"Butters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan J.","family":"McMullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle M.","family":"Haeusler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.11.023_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of Invasive Fungal Disease in Children","volume":"6","author":"Pana","year":"2017","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2025.11.023_bib2","article-title":"Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study","volume":"52","author":"Yeoh","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.cmi.2025.11.023_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27564","article-title":"Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review","volume":"66","author":"Bartlett","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cmi.2025.11.023_bib4","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2025.11.023_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jpids\/piz007","article-title":"Pediatric Mucormycosis: A 10-Year Systematic Review of Reported Cases and Review of the Literature","volume":"8","author":"Otto","year":"2019","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2025.11.023_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jpids\/piae079","article-title":"Occurrence and Case Fatality Rate of Invasive Aspergillosis in Children With Acute Leukemia: A Systematic Review and Meta-analysis","volume":"13","author":"Duus","year":"2024","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2025.11.023_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijid.2007.01.013","article-title":"Central nervous system aspergillosis in children: a systematic review of reported cases","volume":"11","author":"Dotis","year":"2007","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib8","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1542\/peds.2005-1161","article-title":"Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000","volume":"117","author":"Zaoutis","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2025.11.023_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Int Med J"},{"key":"10.1016\/j.cmi.2025.11.023_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jpids\/pix107","article-title":"Mucormycosis in Children: Review and Recommendations for Management","volume":"7","author":"Francis","year":"2018","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2025.11.023_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s12879-016-2005-1","article-title":"Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries","volume":"16","author":"Pana","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib13","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijid.2019.12.017","article-title":"Invasive Scedosporium spp. and Lomentospora prolificans infections in pediatric patients: Analysis of 55 cases from FungiScope\u00ae and the literature","volume":"92","author":"Seidel","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib15","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae285","article-title":"Landscape of Invasive Fusariosis in Pediatric Cancer Patients: Results of a Multicenter Observational Study From Latin America","volume":"11","author":"Carlesse","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmi.2019.05.019","article-title":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children","volume":"25","author":"Warris","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.023_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imj.15592","article-title":"Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology\/oncology setting, 2021","volume":"51","author":"Bupha-Intr","year":"2021","journal-title":"Int Med J"},{"key":"10.1016\/j.cmi.2025.11.023_bib19","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1200\/JCO.22.02224","article-title":"Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update","volume":"41","author":"Lehrnbecher","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2025.11.023_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27806","article-title":"Invasive mold disease of the central nervous system in children and adolescents with cancer or undergoing hematopoietic stem cell transplantation: Analysis of 29 contemporary patients","volume":"66","author":"Lauten","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cmi.2025.11.023_bib21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmicom.2024.105029","article-title":"Invasive mould infection in immunocompromised children: Pulmonary computed tomography findings from two multicentre paediatric cohorts","volume":"1","author":"Yeoh","year":"2024","journal-title":"CMI Commun"},{"key":"10.1016\/j.cmi.2025.11.023_bib23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s11046-023-00714-4","article-title":"The Challenge of Diagnosing Invasive Pulmonary Aspergillosis in Children: A Review of Existing and Emerging Tools","volume":"188","author":"Yeoh","year":"2023","journal-title":"Mycopathologia"},{"key":"10.1016\/j.cmi.2025.11.023_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00247-024-06112-2","article-title":"How accurate is high-resolution computed tomography of the chest in differentiating between pulmonary invasive fungal infections and other pulmonary infections in children with cancer?","volume":"55","author":"Nijhuis","year":"2025","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.cmi.2025.11.023_bib25","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/cid\/ciaa1855","article-title":"Guidance on Imaging for Invasive Pulmonary Aspergillosis and Mucormycosis: From the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC\/MSGERC","volume":"72","author":"Alexander","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000004911","article-title":"Clinical Outcome, Microbiologic Etiology and Pulmonary Tomographic Findings in Children With Cancer and Episodes of Persistent High-risk Febrile Neutropenia","author":"Ib\u00e1\u00f1ez","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2025.11.023_bib27","doi-asserted-by":"crossref","first-page":"684.e11","DOI":"10.1016\/j.cmi.2015.03.019","article-title":"Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis","volume":"21","author":"Jung","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.023_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.semnuclmed.2018.02.003","article-title":"PET\/MRI in Infection and Inflammation","volume":"48","author":"Sollini","year":"2018","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.cmi.2025.11.023_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00259-018-4062-8","article-title":"FDG PET\/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging","volume":"46","author":"Douglas","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cmi.2025.11.023_bib30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/jpc.13809","article-title":"The clinical utility of fluorodeoxyglucose-positron emission tomography for investigation of fever in immunocompromised children","volume":"54","author":"Wang","year":"2018","journal-title":"J Paediatr Cild Health"},{"key":"10.1016\/j.cmi.2025.11.023_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40336-015-0159-2","article-title":"Imaging fungal infections in children","volume":"4","author":"Ankrah","year":"2016","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.cmi.2025.11.023_bib32","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/infdis\/jiad067","article-title":"Radiotracer Development for Fungal-Specific Imaging: Past, Present, and Future","volume":"228","author":"Lai","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib33","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1038\/s41467-025-61700-6","article-title":"(18)F-Fluorodeoxysorbitol PET for noninvasive detection of invasive mold infections: preclinical and first-in-human studies","volume":"16","author":"Ruiz-Gonzalez","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.11.023_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02377-19","article-title":"In Vitro Evaluation of Radiolabeled Amphotericin B for Molecular Imaging of Mold Infections","volume":"64","author":"Page","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000196477","article-title":"Pulmonary aspergillosis: early diagnosis improves survival","volume":"62","author":"von Eiff","year":"1995","journal-title":"Respiration"},{"key":"10.1016\/j.cmi.2025.11.023_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piaf015","article-title":"Utility and Safety of Bronchoalveolar Lavage for Diagnosis and Management of Respiratory Illnesses in Immunocompromised Children","volume":"14","author":"Abraham","year":"2025","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2025.11.023_bib37","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/cid\/ciw592","article-title":"Galactomannan, \u03b2-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis","volume":"63","author":"Lehrnbecher","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib38","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1469-0691.2010.03336.x","article-title":"Diagnosis of invasive fungal infections in immunocompromised children","volume":"16","author":"Dornbusch","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.023_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/myc.13764","article-title":"Is there still a place for serum galactomannan in the diagnosis of invasive aspergillosis in children at high risk and under antifungal prophylaxis?","volume":"67","author":"Gerard","year":"2024","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2025.11.023_bib40","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1128\/JCM.05946-11","article-title":"Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay","volume":"50","author":"Tortorano","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.11.023_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103115","article-title":"The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis","volume":"81","author":"Brown","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.cmi.2025.11.023_bib42","doi-asserted-by":"crossref","first-page":"e01520","DOI":"10.1128\/jcm.01520-22","article-title":"Fungal Integrated Histomolecular Diagnosis Using Targeted Next-Generation Sequencing on Formalin-Fixed Paraffin-Embedded Tissues","volume":"61","author":"Trecourt","year":"2023","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.11.023_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31133","article-title":"Application of cell-free DNA fungal polymerase chain reaction for invasive fungal disease evaluation in pediatric oncology and stem cell transplant patients","volume":"71","author":"Kushner","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cmi.2025.11.023_bib44","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/cid\/ciaf021","article-title":"Concordance of Noninvasive Plasma Cell-free DNA With Invasive Diagnostics for Diagnosis of Invasive Fungal Disease","volume":"80","author":"Lieu","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41525-025-00482-8","article-title":"NGS-based Aspergillus detection in plasma and lung lavage of children with invasive pulmonary aspergillosis","volume":"10","author":"Wesdorp","year":"2025","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.cmi.2025.11.023_bib46","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.023_bib47","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkw056","article-title":"Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre","volume":"71","author":"Boast","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib48","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2025.11.023_bib49","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.11.023_bib50","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jac\/dkz481","article-title":"Evaluation of target attainment of oral posaconazole suspension in immunocompromised children","volume":"75","author":"Lai","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib51","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1093\/jac\/dkz359","article-title":"Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents","volume":"74","author":"Tragiannidis","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib52","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1093\/jac\/dkae373","article-title":"Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children","volume":"79","author":"Weerdenburg","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01197-23","article-title":"A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia","volume":"68","author":"Winchell","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00484-24","article-title":"Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial","volume":"68","author":"Segers","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib55","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.cmi.2025.11.023_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkac060","article-title":"Antifungal use in children with acute leukaemia: state of current evidence and directions for future research","author":"Yeoh","year":"2022","journal-title":"J Antimicrobial Chemotherapy"},{"key":"10.1016\/j.cmi.2025.11.023_bib57","article-title":"Real-life use of isavuconazole in Spanish children and adolescents","author":"Mendoza-Palomar","year":"2025","journal-title":"J Antimicrobial Chemotherapy"},{"key":"10.1016\/j.cmi.2025.11.023_bib58","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijantimicag.2019.01.002","article-title":"Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports","volume":"53","author":"Jeong","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.023_bib59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/0049475519874270","article-title":"Paediatric mucormycosis: tailoring surgical strategies to compliment antifungal chemotherapy. Different strokes for different folks","volume":"50","author":"Srinivas","year":"2020","journal-title":"Trop Doct"},{"key":"10.1016\/j.cmi.2025.11.023_bib60","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1097\/INF.0000000000003608","article-title":"Mucormycosis in Children With Hematologic Malignancies: A Case Series and Review of the Literature","volume":"41","author":"Loeffen","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2025.11.023_bib61","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01550-24","article-title":"Clinical significance and antifungal susceptibility profile of 103 clinical isolates of Scedosporium species complex and Lomentospora prolificans obtained from NIH patients","volume":"63","author":"Czech","year":"2025","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.11.023_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00004-23","article-title":"Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections","volume":"37","author":"Neoh","year":"2024","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/j.cmi.2025.11.023_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00318-20","article-title":"Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates","volume":"64","author":"Wu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib65","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.01160-07","article-title":"In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans","volume":"52","author":"Cuenca-Estrella","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad128","article-title":"Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens","volume":"62","author":"Marinelli","year":"2024","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2025.11.023_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.698662","article-title":"Miltefosine Against Scedosporium and Lomentospora Species: Antifungal Activity and Its Effects on Fungal Cells","volume":"11","author":"Rollin-Pinheiro","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2025.11.023_bib68","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/QCO.0000000000000776","article-title":"How different is invasive fusariosis in pediatric patients than in adults? A systematic review","volume":"34","author":"Rossato","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib69","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/jpids\/piad115","article-title":"Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective","volume":"13","author":"Hsu","year":"2024","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2025.11.023_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.1421","article-title":"P-1239. Systemic Exposure of Olorofim in Children with Invasive Fungal Infections","volume":"12","author":"Cornelissen","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib71","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.cmi.2025.11.023_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.05.013","article-title":"In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and\/or amphotericin B","volume":"28","author":"Escribano","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.023_bib73","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00231-18","article-title":"Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus","volume":"62","author":"du Pr\u00e9","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib74","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1093\/jac\/dkae267","article-title":"In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023","volume":"79","author":"Halliday","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib75","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00434-21","article-title":"In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis","volume":"65","author":"Seyedmousavi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib76","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02789-22","article-title":"In Vitro Activity of the Novel Antifungal Olorofim against Scedosporium and Lomentospora prolificans","volume":"11","author":"Georgacopoulos","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.11.023_bib77","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/myc.13273","article-title":"In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes","volume":"64","author":"Badali","year":"2021","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2025.11.023_bib78","volume":"9","author":"Maertens","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib79","doi-asserted-by":"crossref","first-page":"9194","DOI":"10.1038\/s41467-024-53512-x","article-title":"Structural insights into the inhibition mechanism of fungal GWT1 by manogepix","volume":"15","author":"Dai","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.11.023_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01132-23","article-title":"In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022)","volume":"68","author":"Pfaller","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib81","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01455-23","article-title":"Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants","volume":"68","author":"Hodges","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib82","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib83","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00178-20","article-title":"Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus","volume":"64","author":"Gebremariam","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib84","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/cid\/ciad309","article-title":"Fosmanogepix Therapy of Disseminated Fusarium Infection","volume":"77","author":"Winston","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib85","article-title":"Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico","author":"Smith","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib86","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf185","article-title":"Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)","author":"Hodges","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib87","article-title":"In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies","volume":"7","author":"Rivero-Menendez","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2025.11.023_bib88","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib89","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib90","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02429-19","article-title":"Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1\u21923)-\u03b2-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis","volume":"64","author":"Petraitis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01545-23","article-title":"Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B","volume":"68","author":"Gebremariam","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.023_bib92","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.064","article-title":"871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)","volume":"9","author":"Thompson","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib93","doi-asserted-by":"crossref","DOI":"10.1159\/000545588","article-title":"Recombinant Myeloid Hematopoietic Growth Factors and Clinical Stimulation of Acute Myeloid Leukemia Cells: A Narrative Review","author":"Gilbert","year":"2025","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.cmi.2025.11.023_bib94","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.2446","article-title":"Does Granulocyte-Macrophage Colony-Stimulating Factor as Adjunctive Therapy Affect Mortality in Patients with Hematologic Malignancies?","volume":"12","author":"Snellings","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib95","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac535","article-title":"Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib96","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10875-022-01391-6","article-title":"Efficacy and Safety of Interferon-Gamma in Chronic Granulomatous Disease: a Systematic Review and Meta-analysis","volume":"43","author":"Lugo Reyes","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.cmi.2025.11.023_bib97","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s10096-018-3325-4","article-title":"Adjunctive interferon-\u03b3 immunotherapy in a pediatric case of Aspergillus terreus infection","volume":"37","author":"Assendorp","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib98","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/cncr.20883","article-title":"The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation","volume":"103","author":"Safdar","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2025.11.023_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018202","article-title":"Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions","volume":"13","author":"Wurster","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.11.023_bib100","doi-asserted-by":"crossref","DOI":"10.1111\/myc.70044","article-title":"Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of PD-1 Inhibition as Potential Treatment Option","volume":"68","author":"Mellinghoff","year":"2025","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2025.11.023_bib101","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-Y; in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.023_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.900522","article-title":"Case Report: Immune Checkpoint Blockade Plus Interferon-\u0393 Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis","volume":"13","author":"Serris","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.11.023_bib103","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000530","article-title":"Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection","volume":"5","author":"Banck","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.cmi.2025.11.023_bib104","first-page":"12","article-title":"Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis","author":"Teng","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.cmi.2025.11.023_bib105","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S1470-2045(17)30852-5","article-title":"Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis","volume":"18","author":"Daver","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:47:12Z","timestamp":1775843232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25005786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1198743X25005786"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.11.023","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive mould infection in children \u2013 advances made or obstacles remaining?","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}